DOCSLIB.ORG

Cognitive Function Modulation During Aging: a Focus on L-Alpha-GPE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cognitive Function Modulation During Aging: a Focus on L-Alpha-GPE European Review for Medical and Pharmacological Sciences 2021; 25: 3015-3027 Cognitive function modulation during aging: a focus on L-alpha-GPE G. BIGGIO1, I. DI FAZIO2, C. MARTINI3 1Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy 2Geriatric Evaluation and Rehabilitation Unit Richiedei Foundation, Palazzolo sull’Oglio, Brescia, Italy 3Department of Pharmacy, University of Pisa, Pisa, Italy All authors contributed equally to this work Abstract. – OBJECTIVE: The objectives of Introduction this review are to explore the neuronal path- ways and cellular and molecular mechanisms Cognitive impairment (CI) is a global health involved in both healthy and impaired cognitive issue and, as such, causes a substantial individ- function and to discuss the role of nootropics, ual, economic and societal burden. In addition, in particular, those with cholinergic activity, as promising interventions to preserve and/or im- CI can herald the onset of dementia, which is in- prove cognitive performance in patients in the creasingly associated with significant morbidity symptomatic pre-dementia stage, known as and mortality1,2. During the aging process, there mild cognitive impairment (MCI). is a decline in the ability to perform cognitive MATERIALS AND METHODS: Papers were re- tasks that require one to quickly process/trans- trieved by a PubMed search, using different com- form information to make a decision, includ- binations of keywords (e.g., cognitive function ing measures of speed of processing, working AND aging AND nootropics), without limitations in 1 terms of publication date or language. memory, and executive cognitive function . By RESULTS: Nootropics modulate the activities investigating the factors influencing the course of specific brain pathways involving neurotrans- of cognitive aging may be useful in both preven- mitters and neuromodulators that have distinct tion and treatment strategies aimed at preserv- roles in the cognitive processes. The nootropic ing cognition into advanced age. In the last de- a a L- -glyceryl-phosphoryl-ethanolamine (L- GPE), cade, the notion of successful aging and the idea by virtue of its action as a phospholipid (PL) precursor and acetylcholine (Ach) donor, targets of compression of morbidity – maximizing the neural stem cell aging, cholinergic depletion, oxi- span of effective functioning while minimizing dative stress and microglia activation, loss of en- the length of time in which individuals are func- torhinal cortex neurons, and reduced hippocam- tionally impaired – have been largely discussed pal volume. Cognitive reserve levels may be linked in the medical literature. In this scenario, inves- to the resilience and adaptability of the brain to tigating the neuronal circuits involved in cogni- a cope with age-related cognitive decline. L- GPE tive aging/decline is fundamental in prolonging may contribute to cognitive reserve preservation via its neuronal well-being promoting action. cognitive, physical, and psychological well-be- 3,4 CONCLUSIONS: The substantial burden of ing in older adults . age-related cognitive decline demands effec- Mild cognitive impairment (MCI) occurs tive long-term and well-tolerated interventions along a continuum from normal cognition to aimed at maximizing the span of effective func- dementia. Classified as a mild neurocognitive tioning. The use of inappropriate medication disorder by the World Health Organization may lower cognitive reserve, thus hastening the onset of symptomatic AD, while the use of (WHO), it is increasingly recognized as a rel- nootropics, such as L-a GPE may contribute to evant pathological condition with an estimated cognitive reserve preservation via its neuronal prevalence of 3-19% in the elderly population5,6. well-being promoting action. MCI is gaining recognition as a construct in a range of neurodegenerative diseases, includ- Key Words: Mild cognitive impairment, Aging, Memory, Neu- ing Alzheimer’s Disease (AD) and dementia, ronal plasticity, Nootropics. and its presence as a common feature in Par- kinson’s disease5, and multiple sclerosis7 is in- Corresponding Author: Giovanni Biggio, MD, Ph.D; e-mail: [email protected] 3015 G. Biggio, I. Di Fazio, C. Martini creasingly documented. MCI has been regarded Selection of Evidence as a concept in evolution as definitions of sub- Papers for consideration for the present review types, and diagnostic criteria have been intro- were retrieved by a PubMed search, using dif- duced and modified over time, thus reflecting ferent combinations of keywords (e.g., cognitive the evolving recognition of MCI as an early dis- function AND aging AND nootropics), without ease state in the AD continuum as well as the limitations in terms of publication date and lan- phenotyping-driven patient classification based guage. Papers were selected for inclusion accord- on impairments in multiple or single cognitive ing to their relevance for the topic, as judged by domains. Different diagnostic criteria and sub- the Authors. types of MCI have been proposed and revised over time with the further implementation of the presence of biomarkers indicative for AD patho- Neuronal Plasticity physiology. A very recent and detailed overview and Cognitive Function: of the evolution of MCI diagnostic criteria has the Brain As a Dynamic Organ been recently published6. One important key fea- ture is the observation that MCI causes cognitive Imaging techniques, such as positron emis- changes that do not affect the individuals’ ability sion tomography (PET) and magnetic resonance to carry out everyday activities and, importantly, imaging (MRI), and increasing research in the does not always lead to dementia. In addition, in field of cognitive neuroscience provide a unique some individuals, MCI may even revert, as ob- opportunity to explore brain function by relating served in population-based studies6. Thus, MCI functional imaging to brain cell biology, neuro- as a diagnostic entity has stood the test of time physiology, and metabolism14. Recent advanc- and currently stands as an important treatment es in neuroscience led to a greater awareness of target6,8. However, there is currently no effective the dynamic nature of our brain in which large- pharmacological intervention able to prevent or scale integration among local subnetworks un- slow the course of MCI. A major research effort derlies information processing and cognitive is currently directed towards interventions that tasks – overall, we are increasingly aware that slow the rate of cognitive decline while reducing our brain is restless even at rest15. Thus, it is not cognitive morbidity6. surprising that structural and functional dynamic Nootropics may serve as promising treatment changes take place in the brain across the entire options to strengthen and enhance cognitive per- lifespan (during adolescence or aging)16,17, and in formance across a wide range of brain pathologies both physiological (pregnancy and lactation18) by virtue of their effects on brain dopaminergic, and pathological conditions, including depres- glutamatergic/cholinergic and serotonergic sys- sion19 and Parkinson’s disease20. Evidence of the tems. While research has led to the synthesis of connection between physical changes that occur several drugs with nootropic effects, more re- at individual synapses and behavioral evidence cently, attention has shifted to the identification of learning and memory were provided by Eric of nootropics from natural sources for the pre- Kandel et al21, who coined the term “neuronal vention and management of age-related cognitive plasticity” as the ability of neurons to modify the decline2. Among nootropics of natural origin, strength and efficacy of synaptic transmission L-a-glyceryl-phosphoryl-ethanolamine (L-a- through a diverse number of activity-dependent GPE) is a promising option to target the hallmarks mechanisms. Being plastic, neurons can modify of MCI, including neural stem cell aging, cholin- their molecular, structural and functional out- ergic depletion, oxidative stress and microglia put, through changes in morphology, activation activation, loss of entorhinal cortex neurons, and of intracellular signaling cascades, regulation of reduced hippocampal volume9-13. synaptic density, and neurotransmitter release This work explores the neuronal pathways (or a combination of these events) in response to and the cellular and molecular mechanisms un- specific stimuli. Interestingly, the entire neuronal derpinning both healthy and impaired cognitive network is constantly evolving as being plastic function during aging and discusses the potential and encompassing not only single neurons but of nootropics, particularly those with cholinergic also the extracellular environment. activity, to promote neuronal well-being and pre- Neuronal plasticity is due to the physical and serve and/or improve cognitive performance in chemical changes that occur in our brain during patients with MCI. learning and memory processing. There is evi- 3016 Cognitive impairment and nootropics dence that learning and memory, synaptic plas- memory decline and perhaps slowing cognitive ticity, and neurogenesis are inter-related phenom- impairments associated with neurodegenerative ena. Specifically, the latter two are thought to disorders. Accordingly, a reduction of cholinergic provide a substrate for specific aspects of learning transmission, due to the atrophy of basal nucleus and memory function22. Furthermore, research
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Clinical Significance of Small Molecule Metabolites in the Blood of Patients
    www.nature.com/scientificreports OPEN Clinical signifcance of small molecule metabolites in the blood of patients with diferent types of liver injury Hui Li1,2,5, Yan Wang1,5, Shizhao Ma1,3, Chaoqun Zhang1,4, Hua Liu2 & Dianxing Sun1,4* To understand the characteristic of changes of serum metabolites between healthy people and patients with hepatitis B virus (HBV) infection at diferent stages of disease, and to provide reference metabolomics information for clinical diagnosis of liver disease patients. 255 patients with diferent stages of HBV infection were selected. 3 mL blood was collected from each patient in the morning to detect diferences in serum lysophosphatidylcholine, acetyl-l-carnitine, oleic acid amide, and glycocholic acid concentrations by UFLC-IT-TOF/MS. The diagnostic values of four metabolic substances were evaluated by receiver operating characteristic (ROC) curve. The results showed that the optimal cut-of value of oleic acid amide concentration of the liver cirrhosis and HCC groups was 23.6 mg/L, with a diagnostic sensitivity of 88.9% and specifcity of 70.6%. The diagnostic efcacies of the three substances were similar in the hepatitis and HCC groups, with an optimal cut-of value of 2.04 mg/L, and a diagnostic sensitivity and specifcity of 100% and 47.2%, respectively. The optimal cut-of value of lecithin of the HBV-carrier and HCC groups was 132.85 mg/L, with a diagnostic sensitivity and specifcity of 88.9% and 66.7%, respectively. The optimal cut-of value of oleic acid amide of the healthy and HCC groups was 129.03 mg/L, with a diagnostic sensitivity and specifcity of 88.4% and 83.3%, respectively.
    [Show full text]
  • An Integrated Meta-Analysis of Peripheral Blood Metabolites and Biological Functions in Major Depressive Disorder
    Molecular Psychiatry https://doi.org/10.1038/s41380-020-0645-4 ARTICLE An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder 1,2,3 1,2,3 1,2,3 1,3 1,3 4,5 1,3 1,3 Juncai Pu ● Yiyun Liu ● Hanping Zhang ● Lu Tian ● Siwen Gui ● Yue Yu ● Xiang Chen ● Yue Chen ● 1,2,3 1,3 1,3 1,3 1,3 1,2,3 Lining Yang ● Yanqin Ran ● Xiaogang Zhong ● Shaohua Xu ● Xuemian Song ● Lanxiang Liu ● 1,2,3 1,3 1,2,3 Peng Zheng ● Haiyang Wang ● Peng Xie Received: 3 June 2019 / Revised: 24 December 2019 / Accepted: 10 January 2020 © The Author(s) 2020. This article is published with open access Abstract Major depressive disorder (MDD) is a serious mental illness, characterized by high morbidity, which has increased in recent decades. However, the molecular mechanisms underlying MDD remain unclear. Previous studies have identified altered metabolic profiles in peripheral tissues associated with MDD. Using curated metabolic characterization data from a large sample of MDD patients, we meta-analyzed the results of metabolites in peripheral blood. Pathway and network analyses were then performed to elucidate the biological themes within these altered metabolites. We identified 23 differentially 1234567890();,: 1234567890();,: expressed metabolites between MDD patients and controls from 46 studies. MDD patients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric acid, phosphatidylcholine (32:1), and taurochenode- soxycholic acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid, pyruvic acid, palmitoleic acid, L-serine, oleic acid, myo-inositol, dodecanoic acid, L-methionine, hypoxanthine, palmitic acid, L-tryptophan, kynurenic acid, taurine, and 25-hydroxyvitamin D compared with controls.
    [Show full text]
  • Effects of Long-Term Acetyl-L-Carnitine Administration in Ratsfii: Protection Against the Disrupting Effect of Stress on the Acquisition of Appetitive Behavior
    Neuropsychopharmacology (2003) 28, 683–693 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Effects of Long-Term Acetyl-L-Carnitine Administration in RatsFII: Protection Against the Disrupting Effect of Stress on the Acquisition of Appetitive Behavior 1 1 1 1 2 Flavio Masi , Benedetta Leggio , Giulio Nanni , Simona Scheggi , M Graziella De Montis , Alessandro 1 1 ,1 Tagliamonte , Silvia Grappi and Carla Gambarana* 1 2 Department of Neuroscience, Pharmacology Unit, University of Siena, Siena, Italy; Department of ‘Scienze del Farmaco’, University of Sassari, Sassari, Italy Long-term acetyl-L-carnitine (ALCAR) administration prevents the development of escape deficit produced by acute exposure to unavoidable stress. However, it does not revert the escape deficit sustained by chronic stress exposure. Rats exposed to chronic stress show a low dopamine (DA) output in the nucleus accumbens shell (NAcS) and do not acquire an appetitive behavior sustained by the earning of vanilla sugar (VS) made contingent on the choice of one of the two divergent arms of a Y-maze (VS-sustained appetitive behavior, VAB), while control rats consistently do. The present study shows that ALCAR treatment in rats exposed to a 7-day stress protocol prevented a decrease in DA output in the NAcS and medial prefrontal cortex (mPFC) of rats, and that it strengthened the DA response to VS consummation in the same two areas. Moreover, rats treated with long-term ALCAR or exposed to chronic stress while treated with ALCAR acquired VAB as efficiently as control rats. Moreover, VAB acquisition in stressed rats treated with ALCAR coincided with the reversal of the deficits in escape and in dopaminergic transmission in the NAcS.
    [Show full text]
  • Potential Role of L-Carnitine in Autism Spectrum Disorder
    Journal of Clinical Medicine Review Potential Role of L-Carnitine in Autism Spectrum Disorder Alina K˛epka 1,† , Agnieszka Ochoci ´nska 1,*,† , Sylwia Chojnowska 2 , Małgorzata Borzym-Kluczyk 3, Ewa Skorupa 1, Małgorzata Kna´s 2 and Napoleon Waszkiewicz 4 1 Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland; [email protected] (A.K.); [email protected] (E.S.) 2 Faculty of Health Sciences, Lomza State University of Applied Sciences, 18-400 Lomza, Poland; [email protected] (S.C.); [email protected] (M.K.) 3 Department of Pharmaceutical Biochemistry, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] 4 Department of Psychiatry, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-22-815-73-01 † These authors are sharing the first place. Both contributed equally to this work. Abstract: L-carnitine plays an important role in the functioning of the central nervous system, and especially in the mitochondrial metabolism of fatty acids. Altered carnitine metabolism, abnormal fatty acid metabolism in patients with autism spectrum disorder (ASD) has been documented. ASD is a complex heterogeneous neurodevelopmental condition that is usually diagnosed in early child- hood. Patients with ASD require careful classification as this heterogeneous clinical category may include patients with an intellectual disability or high functioning, epilepsy, language impairments, or associated Mendelian genetic conditions. L-carnitine participates in the long-chain oxidation of fatty acids in the brain, stimulates acetylcholine synthesis (donor of the acyl groups), stimulates ex- pression of growth-associated protein-43, prevents cell apoptosis and neuron damage and stimulates Citation: K˛epka,A.; Ochoci´nska,A.; neurotransmission.
    [Show full text]
  • Acetylcarnitine Is a Candidate Diagnostic and Prognostic
    Published OnlineFirst March 14, 2016; DOI: 10.1158/0008-5472.CAN-15-3199 Cancer Integrated Systems and Technologies Research Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma Yonghai Lu1, Ning Li2, Liang Gao3, Yong-Jiang Xu4, Chong Huang2, Kangkang Yu2, Qingxia Ling2, Qi Cheng2, Shengsen Chen2, Mengqi Zhu2, Jinling Fang1, Mingquan Chen2, and Choon Nam Ong1,3 Abstract The identification of serum biomarkers to improve the diag- carcinoma tumors and matched normal tissues. Post hoc analysis nosis and prognosis of hepatocellular carcinoma has been elusive to evaluate serum diagnosis and progression potential further to date. In this study, we took a mass spectroscopic approach to confirmed the diagnostic capability of serum acetylcarnitine. characterize metabolic features of the liver in hepatocellular Finally, an external validation in an independent batch of 58 carcinoma patients to discover more sensitive and specific serum samples (18 hepatocellular carcinoma patients, 20 liver biomarkers for diagnosis and progression. Global metabolic cirrhosis patients, and 20 healthy individuals) verified that profiling of 50 pairs of matched liver tissue samples from hepa- serum acetylcarnitine was a meaningful biomarker reflecting tocellular carcinoma patients was performed. A series of 62 hepatocellular carcinoma diagnosis and progression. These find- metabolites were found to be altered significantly in liver tumors; ings present a strong new candidate biomarker for hepatocellular however, levels of acetylcarnitine correlated most strongly with carcinoma with potentially significant diagnostic and prognostic tumor grade and could discriminate between hepatocellular capabilities. Cancer Res; 76(10); 2912–20. Ó2016 AACR. Introduction early and accurate diagnosis of hepatocellular carcinoma, there have been a number of previous investigations on gene expres- Hepatocellular carcinoma is the most common type of pri- sion, miRNA profiles, and protein expression of hepatocellular mary liver cancer and has become a major global health issue.
    [Show full text]
  • The Prebiotic Inulin Beneficially Modulates the Gut-Brain Axis by Enhancing Metabolism in an Apoe4 Mouse Model" (2018)
    University of Kentucky UKnowledge Theses and Dissertations--Pharmacology and Nutritional Sciences Pharmacology and Nutritional Sciences 2018 THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT- BRAIN AXIS BY ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL Jared D. Hoffman University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0002-9424-3526 Digital Object Identifier: https://doi.org/10.13023/etd.2018.405 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Hoffman, Jared D., "THE PREBIOTIC INULIN BENEFICIALLY MODULATES THE GUT-BRAIN AXIS BY ENHANCING METABOLISM IN AN APOE4 MOUSE MODEL" (2018). Theses and Dissertations-- Pharmacology and Nutritional Sciences. 24. https://uknowledge.uky.edu/pharmacol_etds/24 This Doctoral Dissertation is brought to you for free and open access by the Pharmacology and Nutritional Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacology and Nutritional Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • A Chemoinformatics Approach for the in Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food
    Diploma Thesis A Chemoinformatics Approach for the In Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food Anna Maria Tsakiroglou Thesis Supervisors: Assoc. Prof.: Kouskoumvekaki Irene Assoc. Prof.: Topakas Evangelos February 2016 Dedication To all the people who made the realization of this work possible. My supervisor for the most useful input and advice along the way. My parents for their unending support. To Katerina, and last, but not least, to Panagiotis, for always being there for me, even from so far away. You are awesome. i ii Abstract The overall objective of this project was the development of a systematic approach for identifying potential interactions between plant-based food and marketed psycholeptics and psychoanaleptic drugs. The problem was addressed, initially, by pairing psychiatric agents and phytochemicals to their common protein targets, using information available in online databases, such as NutriChem 1.0 [21] and Drugbank [16] and constructing the food-drug interaction networks. Thereupon, a search for additional phytochemicals that would be expected to interact with targets of psychiatric drugs was carried out. More specifically, three protein targets, P07550, P28222 and P14416 were selected, based on their frequency of interaction with both psycholeptics and psychoanaleptics and the avail- ability of 3D structural information in PDB [19]. For these protein targets, ligand-based pharmacophoric hypothesis were generated, using experimental activity data from the literature, and the HypoGen feature of Accelrys Discovery Studio (DS) [7]. The phar- macophore models were validated using external test sets and Fisher’s method. Sub- sequently, the models were used as queries to screen the NutriChem 1.0 database for more potentially active phytochemicals.
    [Show full text]
  • Name Type Sub-Subtype Acetylcarnitine Lipid Carnitine
    Name Type Sub-Subtype acetylcarnitine Lipid Carnitine metabolism acetylphosphate Energy Oxidative phosphorylation adrenate (22:4n6) Lipid Long chain fatty acid alanine Amino acid Alanine and aspartate metabolism alpha-hydroxyisocaproate Amino acid Valine, leucine and isoleucine metabolism alpha-hydroxyisovalerate Amino acid Valine, leucine and isoleucine metabolism alpha-tocopherol Cofactors and Tocopherol metabolism vitamins andro steroid monosulfate 2* Lipid Sterol/Steroid androsterone sulfate Lipid Sterol/Steroid arabitol Carbohydrate Nucleotide sugars, pentose metabolism arachidonate (20:4n6) Lipid Long chain fatty acid arginine Amino acid Urea cycle; arginine-, proline-, metabolism asparagine Amino acid Alanine and aspartate metabolism azelate (nonanedioate) Lipid Fatty acid, dicarboxylate benzoate Xenobiotics Benzoate metabolism beta-alanine Amino acid Alanine and aspartate metabolism beta-hydroxyisovalerate Amino acid Valine, leucine and isoleucine metabolism betaine Amino acid Glycine, serine and threonine metabolism bilirubin (E,E)* Cofactors and Hemoglobin and porphyrin vitamins metabolism bilirubin (E,Z or Z,E)* Cofactors and Hemoglobin and porphyrin vitamins metabolism bilirubin (Z,Z) Cofactors and Hemoglobin and porphyrin vitamins metabolism biliverdin Cofactors and Hemoglobin and porphyrin vitamins metabolism butyrylcarnitine Lipid Fatty acid metabolism (also BCAA metabolism) C-glycosyltryptophan* Amino acid Tryptophan metabolism caprate (10:0) Lipid Medium chain fatty acid caproate (6:0) Lipid Medium chain fatty acid caprylate
    [Show full text]
  • Acetylcarnitine and Cholinergic Receptors
    (2) P. L. Schiff, Jr., and R. W. Doskotch, Lloydia, 33,404 (1970). ACKNOWLEDGMENTS (3) C.-H. Chen and J. Wu, Taiwan Yao Hsueh Tsa Chih, 28, 121 (1976). Adapted in part from the theses submitted by T.-M. Chen and C. Lee (4) M. Shamma, M. J. Hillman, and C.D. Jones, Chem. Reu., 69,779 to the National Taiwan University in partial fulfillment of the Master (1969). of Science degree requirements. (5) V.Simanek, V. Preininger, and J. Lasovsky, Coll. Czech. Chem. Supported by the National Science Council of the Republic of Commun., 41,1050 (1976). China. (6) G.Habermehl, J. Schunk, and G. Schaden, Justus Liebigs Ann. The authors thank Dr. Edward H. Fairchild and Dr. Jinn Wu, College Chem., 742, 138 (1970). of Pharmacy, Ohio State University, for measurement of some PMR and (7) C. Moulis, J. Gleye, and E. Stanislas, Phytochemistry, 16,1283 mass spectra and Dr. Kuo-Hsiung Lee, School of Pharmacy, University (1977). of North Carolina at Chapel Hill, for measurement of the high-resolution (8) H.Suguna and B. R. Pai, Coll. Czech. Chem. Commun., 41,1219 mass spectra. They also thank Dr. B. R. Pai, Department of Chemistry, (1976). Presidency University, Madras, India, for an authentic sample of 3- (9) J. Schmutz, Helu. Chim. Acta, 42,335 (1959). hydroxy-2-methoxy-l0,ll-methylenedioxyberbineand Dr. C. Moulis, (10) T. Kametani, M. Takeshita, and S. Takano, J. Chem. SOC.Perkin Faculty of Pharmaceutical Sciences, University of Toulouse, France, for I, 1972,2834. authentic samples of pseudocolumbamine and dehydropseudocheilan- (11) T. Kametani, Y.Hirai, F.
    [Show full text]
  • 3.2 Choline and Its Products Acetylcholine and Phosphatidylcholine
    3.2 Choline and Its Products Acetylcholine and Phosphatidylcholine AU1 Choline R. J. Wurtman . M. Cansev . I. H. Ulus 1 Introduction ...................................................................................... 3 2 Choline in the Blood ............................................................................. 3 2.1 Sources of Plasma Choline . ................................................................. 4 2.1.1 Dietary Choline ..................................................................................... 4 2.1.2 Endogenous Choline Synthesis . ................................................................. 5 2.1.3 Choline‐Containing Membrane Phospholipids . ................................... 9 2.2 Fates of Circulating Choline . ................................................................ 10 2.2.1 Choline as a Source of Methyl Groups (Choline Oxidase System) . 12 2.3 Effects of Physiologic or Pathologic States on Plasma Choline .................................. 15 3 Choline in the Brain ............................................................................ 16 3.1 Sources of Brain Choline . ................................................................ 16 3.1.1 Uptake of Circulating Choline into the Brain . .................................. 16 3.1.2 Liberation from Membrane PC . ................................................................ 17 3.1.3 Reutilization of Choline Formed from Hydrolysis of Acetylcholine . 18 3.1.4 De Novo Synthesis of Phosphatidylcholine and Choline . .................................
    [Show full text]
  • White Blood Cell; HBG: Hemoglobin;
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2018 Supplementary Table 1 Treatment outcome of CBC and biochemical examination Value (mean ± SD) P1 P 2 Day 0 Day 15 Day 30 WBC (* 10^9/L) 10.198 ± 9.836 4.119 ± 2.657 5.467 ± 4.392 0.048 0.076 HBG (g/L) 80.8 ± 16.8 71.0 ± 13.3 76.7 ± 17.6 0.002 0.172 PLT (* 10^9/L) 93.2 ± 88.3 60.0 ± 53.8 87.1 ± 85.3 0.042 0.234 ALT (U/L) 20.2 ± 8.9 21.5 ± 13.0 23.6 ± 9.5 0.577 0.222 AST (U/L) 20.1 ± 5.4 22.5 ± 11.7 24.6 ± 9.9 0.48 0.154 BUN (mg/dL) 8.53 ± 9.01 7.81 ± 7.65 6.75 ± 4.36 0.809 0.515 Ccr (μmol/L) 79.82 ± 60.50 70.46 ± 38.89 68.73 ± 37.65 0.392 0.259 WBC: white blood cell; HBG: hemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate transaminase; BUN: urea nitrogen; Ccr: creatinine Supplemental Table 2 List of 390 identified metabolites in serum samples Super Sub Pathway Biochemical Name KEGG HMDB Pathway glycine C00037 HMDB00123 N-acetylglycine HMDB00532 sarcosine C00213 HMDB00271 dimethylglycine C01026 HMDB00092 Glycine, Serine betaine C00719 HMDB00043 and Threonine serine C00065 HMDB00187 Metabolism N-acetylserine HMDB02931 beta-hydroxypyruvate C00168 HMDB01352 threonine C00188 HMDB00167 N-acetylthreonine homoserine C00263 HMDB00719 alanine C00041 HMDB00161 Alanine and N-acetylalanine C02847 HMDB00766 Aspartate aspartate C00049 HMDB00191 Metabolism asparagine C00152 HMDB00168 N-acetylaspartate (NAA) C01042 HMDB00812 glutamate C00025 HMDB00148 Glutamate glutamine C00064 HMDB00641 Metabolism pyroglutamine* histidine
    [Show full text]